PROJECT

Projects

Environmental & Social Review Summary

Project Number

45174

Company Name

ASPEN TREASURY IRELAND LIMITED

Date ESRS Disclosed

Jun 30, 2021

Country

South Africa

Region

Africa

Last Updated Date

Oct 5, 2021

Environmental Category

B - Limited

Status

Active

Previous Events

Approved : May 27, 2021
Signed : Jun 30, 2021
Invested : Sep 30, 2021

Sector

other

Industry

other

Department

Regional Industry - MAS Africa

Project Description

The proposed investment is a financing package comprising an A loan  of EUR200 million and up to EUR400m in B/Parallel loans to Aspen Finance (Pty) Limited, which is a wholly owned subsidiary of Aspen Pharmacare Holdings Limited (‘Aspen’ or the ‘company’) or the ‘Group’, https://www.aspenpharma.com/), a South African based and Johannesburg Stock Exchange (‘JSE’) listed global specialty and branded pharmaceuticals company with a presence in both emerging and developed markets.

Aspen is Africa’s largest pharmaceuticals company, a manufacturer and distributor of lifesaving medicines and Active Pharmaceutical Ingredients (‘APIs’). The company focuses on marketing and manufacturing a broad range of post-patent, branded medicines and domestic brands covering both hospital and consumer markets through their key business segments.  The company’s key business segments are Manufacturing and Commercial Pharmaceuticals. Commercial Pharmaceuticals comprises Regional Brands and Sterile Focus Brands that include vaccine, anesthetic and thrombosis products. The company’s manufacturing footprint includes seven API and 16 Finished Dose Form production facilities situated across Africa, Asia, Europe and the United States (US). The company supplies medicines to over 150 emerging and developed countries (including 18 in Africa) through its 71 established offices in more than 50 countries. The API manufacturing network comprises seven owned facilities, three located in the Netherlands (two in Oss and one in Boxtel), one in the US (Sioux City), two in France (Notre Dame de Bondeville) and one in South Africa (Cape Town). In addition, the company has two API manufacturing blocks situated at Laurus Laboratories in India. These sites provide Aspen with specialized API manufacturing capabilities for their own use, as well as third party commercial opportunities. Aspen is also a ‘front-line’ manufacturer of essential COVID-19 drugs by way of the agreement recently signed with Janssen (a Johnson & Johnson company) for the related technology transfer to enable Aspen to compound, finish, fill and package the Janssen COVID-19 vaccine which has further induced a demand on the company’s manufacturing capacity.

This proposed investment therefore seeks to support Aspen by providing long tenor funding for capital expenditure, acquisitions and the refinancing of Aspen’s existing debt and working capital needs for its global business including, but not exclusively limited to addressing the surge in demand for pharmaceuticals resulting from the COVID-19 pandemic (the ‘project’). The project will be a part of IFC’s Global Health Platform (‘GHP’) which is focused on supporting a ‘front-line’ manufacturer of essential COVID-19 vaccines and drugs, which will be central to the effort to overcome the current pandemic.

Overview of IFC's Scope of Review

 Considering the nature of the investment (i.e. corporate loans with undefined use of proceeds and large number of facilities), IFC’s review has focused on Aspen’s corporate environmental, occupational health and safety (‘OHS’), and social management systems with visits to a sample of its facilities to review on-site implementation of these systems.

As part of the appraisal, IFC reviewed information provided by Aspen as well as extensive information publicly disclosed on Aspen’s website, including: the company’s corporate occupational safety, health and environmental (‘SHE’) policies, procedures and standards; human resources (‘HR’) policies, procedures and disclosures; SHE key performance indicators and sustainability reports. Additionally, site appraisal visits were undertaken to Aspen’s plants in Gqeberha, South Africa and Nairobi, Kenya on April 20 - 21 2021. Finally, the appraisal included discussions with the company’s senior management, corporate and facility level personnel responsible for SHE, HR management and utilities management via video conferencing and during the site visits.

Identified Applicable Performance Standards:

While all Performance Standards are applicable to this investment, IFC’s environmental and social due diligence indicates that the investment will have impacts which must be managed in a manner consistent with the following Performance Standards.

PS1: Assessment and Management of Environmental and Social Risks and Impacts

PS2: Labor and Working Conditions

PS3: Resource Efficiency and Pollution Prevention

PS4: Community Health, Safety, and Security

The company plans to use its existing sterile production facilities in Gqeberha for COVID-19 vaccine production, which: (i) will not require new land acquisition and is located in a light industrial zone in an urban setting removed from any sensitive habitats, high biodiversity values, or where cultural heritage may be impacted; and (ii) does not overlap with or impact on local indigenous peoples’ communities and their lands and resources. Similarly, most of the company operations are located in well developed industrial zones.

As such, the project is not expected to result in the impacts that must be managed in accordance with PS 5 (Land Acquisition and Involuntary Resettlement), PS 6 (Biodiversity Conservation and Sustainable Natural Resource Management), PS7 (Indigenous Peoples), and PS8 (Cultural Heritage).

If IFC’s investment proceeds, IFC will periodically review the project’s ongoing compliance with the Performance Standards.

E & S Project Categorization and Applicable Standard

Environmental and Social Mitigation Measures

Stakeholder Engagement

Broad Community Support